To evaluate the efficacy of subcutaneous (SC) KPL-716 in reducing pruritis in subjects with moderate to severe PN experiencing severe itching.
Sponsor(s)
Kiniska Pharmaceuticals, Ltd.
Principal Investigator(s)
Dr. Jonathan Silverberg MD, PHD, MPH
Request Information